We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
For investors seeking momentum, Amplify Seymour Cannabis ETF (CNBS - Free Report) is probably on the radar. The fund just hit a 52-week high and is up 199.07% from its 52-week low price of $13.96/share.
But are there more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea of where it might be headed:
CNBS in Focus
The fund employs an active strategy to deliver diversified exposure across the U.S. cannabis ecosystem. The product charges 76 bps in annual fees (See: All Marijuana ETFs).
Why the Move?
The cannabis sector been drawing renewed attention lately, supported by President Trump’s plan to ease federal regulations on marijuana, making it a key policy tailwind. Reclassifying marijuana to a lower-risk category drug could significantly boost research funding and improve the sector’s access to more capital by easing legal constraints.
More Gains Ahead?
CNBS might continue its strong performance in the near term, with a positive weighted alpha of 19.45 (as per Barchart.com), which gives cues of a further rally.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cannabis ETF (CNBS) Hits New 52-Week High
For investors seeking momentum, Amplify Seymour Cannabis ETF (CNBS - Free Report) is probably on the radar. The fund just hit a 52-week high and is up 199.07% from its 52-week low price of $13.96/share.
But are there more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea of where it might be headed:
CNBS in Focus
The fund employs an active strategy to deliver diversified exposure across the U.S. cannabis ecosystem. The product charges 76 bps in annual fees (See: All Marijuana ETFs).
Why the Move?
The cannabis sector been drawing renewed attention lately, supported by President Trump’s plan to ease federal regulations on marijuana, making it a key policy tailwind. Reclassifying marijuana to a lower-risk category drug could significantly boost research funding and improve the sector’s access to more capital by easing legal constraints.
More Gains Ahead?
CNBS might continue its strong performance in the near term, with a positive weighted alpha of 19.45 (as per Barchart.com), which gives cues of a further rally.